This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-125b-5p | ABCB9 | 0.4 | 0.2546 | 0.46 | 0.14647 | mirMAP | -0.22 | 0.00097 | NA | |
2 | hsa-miR-125b-5p | ABTB1 | 0.4 | 0.2546 | -0.09 | 0.79256 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.2 | 0.00439 | NA | |
3 | hsa-miR-125b-5p | ACAP3 | 0.4 | 0.2546 | -0.33 | 0.38761 | miRNATAP | -0.28 | 0.00052 | NA | |
4 | hsa-miR-125b-5p | ADAMTS13 | 0.4 | 0.2546 | 0.09 | 0.85937 | mirMAP | -0.28 | 0.0081 | NA | |
5 | hsa-miR-125b-5p | ADAP1 | 0.4 | 0.2546 | 1.46 | 0.03319 | mirMAP | -0.3 | 0.04383 | NA | |
6 | hsa-miR-125b-5p | ADRM1 | 0.4 | 0.2546 | 0.24 | 0.39709 | miRNAWalker2 validate | -0.32 | 0 | NA | |
7 | hsa-miR-125b-5p | AIFM1 | 0.4 | 0.2546 | 0.08 | 0.68492 | miRNATAP | -0.15 | 0.00022 | NA | |
8 | hsa-miR-125b-5p | AKAP1 | 0.4 | 0.2546 | 0.93 | 0.00358 | miRNATAP | -0.15 | 0.02649 | NA | |
9 | hsa-miR-125b-5p | AKT1 | 0.4 | 0.2546 | 0.04 | 0.7925 | miRNAWalker2 validate; miRTarBase | -0.11 | 0.0004 | NA | |
10 | hsa-miR-125b-5p | AMIGO3 | 0.4 | 0.2546 | 0.1 | 0.79393 | mirMAP | -0.27 | 0.00042 | NA | |
11 | hsa-miR-125b-5p | ANAPC16 | 0.4 | 0.2546 | -0.03 | 0.86927 | MirTarget | -0.1 | 0.00838 | NA | |
12 | hsa-miR-125b-5p | ARFRP1 | 0.4 | 0.2546 | -0.03 | 0.91973 | mirMAP | -0.26 | 1.0E-5 | NA | |
13 | hsa-miR-125b-5p | ARMC5 | 0.4 | 0.2546 | -0.29 | 0.34639 | mirMAP | -0.19 | 0.00543 | NA | |
14 | hsa-miR-125b-5p | ARMC6 | 0.4 | 0.2546 | -0.02 | 0.92912 | mirMAP | -0.26 | 0 | NA | |
15 | hsa-miR-125b-5p | ATP5B | 0.4 | 0.2546 | 0.22 | 0.27748 | miRNAWalker2 validate | -0.14 | 0.00062 | NA | |
16 | hsa-miR-125b-5p | ATP5G2 | 0.4 | 0.2546 | 0.15 | 0.56128 | MirTarget; miRNATAP | -0.28 | 0 | NA | |
17 | hsa-miR-125b-5p | AURKB | 0.4 | 0.2546 | 0.3 | 0.65138 | miRNAWalker2 validate | -0.45 | 0.00165 | NA | |
18 | hsa-miR-125b-5p | B3GALNT2 | 0.4 | 0.2546 | 0.28 | 0.24769 | MirTarget | -0.11 | 0.03902 | NA | |
19 | hsa-miR-125b-5p | B4GALT3 | 0.4 | 0.2546 | 0.45 | 0.0403 | miRNAWalker2 validate | -0.19 | 3.0E-5 | NA | |
20 | hsa-miR-125b-5p | BAK1 | 0.4 | 0.2546 | 0.35 | 0.26822 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.17 | 0.01139 | 24643683; 27386402; 21823019; 18056640; 23928699; 20460378 | miR 125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1; Moreover we demonstrated that the pro-apoptotic Bcl-2 antagonist killer 1 Bak1 was a direct target of miR-125b; Taken together; our data strongly support an important role for miR-125b on conferring TMZ resistance through targeting Bak1 expression;We subsequently evaluated the effect of miR-125b-1 reactivation on the expression and protein levels of BAK1 a target of miR-125b;An in vitro cytotoxicity assay and apoptosis assay using CCK-8 assay and flow cytometry were carried out to detect the effect of miR-125b and Bak1 on cisplatin resistance of cells; Real-time PCR Western blotting and luciferase reporter assay were used to detect whether Bak1 is a target of miR-125b; Moreover Bak1 was a direct target of miR-125b and down-regulation of Bak1 suppressed cisplatin-induced apoptosis and led to an increased resistance to cisplatin; Our study indicates that miR-125b has a significantly promoting effect on chemoresistance of C13* cells and up-regulation of miR-125b expression contributes to cisplatin resistance through suppression of Bak1 expression;In addition transfection of synthetic miR-125b stimulated androgen-independent growth of CaP cells and down-regulated the expression of Bak1;In contrast miR-125b sponge impaired the anti-apoptotic effect of OCT4 along with the upregulated expression of BAK1; Significantly Luciferase assay showed that the activity of the wild-type BAK1 3'-untranslated region reporter was suppressed and this suppression was diminished when the miR-125b response element was mutated or deleted; In addition we observed negative correlation between levels of BAK1 and OCT4 and positive between OCT4 and miR-125b in primary cervical cancers; These findings suggest an undescribed regulatory pathway in cervical cancer by which OCT4 directly induces expression of miR-125b which inhibits its direct target BAK1 leading to suppression of cervical cancer cell apoptosis;Moreover we demonstrated that the pro-apoptotic Bcl-2 antagonist killer 1 Bak1 is a direct target of miR-125b; Restoring Bak1 expression by either miR-125b inhibitor or re-expression of Bak1 in miR-125b-overexpressing cells recovered Taxol sensitivity overcoming miR-125-mediated Taxol resistance; Taken together our data strongly support a central role for miR-125b in conferring Taxol resistance through the suppression of Bak1 expression |
21 | hsa-miR-125b-5p | BBC3 | 0.4 | 0.2546 | 0 | 0.9971 | miRNAWalker2 validate; miRTarBase | -0.4 | 0.00038 | 25184537 | Thus far two of these target genes BBC3 and NEU1 that are tumor suppressor genes but not yet studied in PDAC appear to be functional targets of miR-125b since knockdown of miR125b caused their up regulation |
22 | hsa-miR-125b-5p | BCKDK | 0.4 | 0.2546 | -0.01 | 0.94665 | miRNAWalker2 validate | -0.16 | 0.00011 | NA | |
23 | hsa-miR-125b-5p | BDH1 | 0.4 | 0.2546 | 0.8 | 0.06208 | MirTarget | -0.3 | 0.00097 | NA | |
24 | hsa-miR-125b-5p | BRMS1 | 0.4 | 0.2546 | 0.1 | 0.68952 | MirTarget | -0.22 | 4.0E-5 | NA | |
25 | hsa-miR-125b-5p | C22orf29 | 0.4 | 0.2546 | -0.02 | 0.94291 | mirMAP | -0.16 | 0.00083 | NA | |
26 | hsa-miR-125b-5p | C7orf43 | 0.4 | 0.2546 | -0.33 | 0.21866 | miRNATAP | -0.16 | 0.00578 | NA | |
27 | hsa-miR-125b-5p | CARHSP1 | 0.4 | 0.2546 | -0.04 | 0.87116 | miRNAWalker2 validate | -0.15 | 0.00364 | NA | |
28 | hsa-miR-125b-5p | CARS2 | 0.4 | 0.2546 | -0.07 | 0.77027 | MirTarget | -0.22 | 2.0E-5 | NA | |
29 | hsa-miR-125b-5p | CBFA2T2 | 0.4 | 0.2546 | -0.1 | 0.72617 | mirMAP | -0.2 | 0.00126 | NA | |
30 | hsa-miR-125b-5p | CCDC124 | 0.4 | 0.2546 | -0.05 | 0.89199 | miRNAWalker2 validate | -0.35 | 0 | NA | |
31 | hsa-miR-125b-5p | CD320 | 0.4 | 0.2546 | 0.16 | 0.67971 | miRNAWalker2 validate | -0.28 | 0.00109 | NA | |
32 | hsa-miR-125b-5p | CDK16 | 0.4 | 0.2546 | 0.31 | 0.11148 | MirTarget; miRNATAP | -0.16 | 5.0E-5 | NA | |
33 | hsa-miR-125b-5p | CDRT4 | 0.4 | 0.2546 | -0.23 | 0.53257 | miRNAWalker2 validate | -0.2 | 0.01004 | NA | |
34 | hsa-miR-125b-5p | CENPB | 0.4 | 0.2546 | 0.18 | 0.45877 | mirMAP | -0.23 | 0 | NA | |
35 | hsa-miR-125b-5p | CENPO | 0.4 | 0.2546 | 0.26 | 0.36646 | mirMAP | -0.24 | 0.0001 | NA | |
36 | hsa-miR-125b-5p | CHPF2 | 0.4 | 0.2546 | 0.12 | 0.60854 | miRNAWalker2 validate | -0.21 | 1.0E-5 | NA | |
37 | hsa-miR-125b-5p | CLN6 | 0.4 | 0.2546 | 0.16 | 0.5387 | MirTarget | -0.16 | 0.00286 | NA | |
38 | hsa-miR-125b-5p | COMT | 0.4 | 0.2546 | 0.24 | 0.34273 | mirMAP | -0.14 | 0.01283 | NA | |
39 | hsa-miR-125b-5p | COPS7B | 0.4 | 0.2546 | -0.02 | 0.90307 | MirTarget; miRNATAP | -0.17 | 4.0E-5 | NA | |
40 | hsa-miR-125b-5p | COX7C | 0.4 | 0.2546 | 0.25 | 0.32261 | miRNAWalker2 validate | -0.19 | 0.00049 | NA | |
41 | hsa-miR-125b-5p | CRTC1 | 0.4 | 0.2546 | -0.19 | 0.60098 | miRNAWalker2 validate | -0.17 | 0.03083 | NA | |
42 | hsa-miR-125b-5p | CTNNBIP1 | 0.4 | 0.2546 | 0.53 | 0.06928 | mirMAP | -0.14 | 0.02281 | NA | |
43 | hsa-miR-125b-5p | CYB561 | 0.4 | 0.2546 | 0.97 | 0.00414 | mirMAP | -0.32 | 1.0E-5 | NA | |
44 | hsa-miR-125b-5p | DDR1 | 0.4 | 0.2546 | 0.94 | 0.01674 | mirMAP | -0.18 | 0.03683 | NA | |
45 | hsa-miR-125b-5p | DDX11 | 0.4 | 0.2546 | 0.77 | 0.09016 | mirMAP | -0.28 | 0.00388 | NA | |
46 | hsa-miR-125b-5p | DDX54 | 0.4 | 0.2546 | 0.02 | 0.93488 | MirTarget | -0.24 | 0 | NA | |
47 | hsa-miR-125b-5p | DGAT1 | 0.4 | 0.2546 | 0.63 | 0.07983 | miRNAWalker2 validate; miRTarBase | -0.38 | 0 | NA | |
48 | hsa-miR-125b-5p | DGCR14 | 0.4 | 0.2546 | -0.13 | 0.51632 | mirMAP | -0.16 | 0.00017 | NA | |
49 | hsa-miR-125b-5p | DIS3L2 | 0.4 | 0.2546 | -0.02 | 0.9167 | MirTarget | -0.17 | 1.0E-5 | NA | |
50 | hsa-miR-125b-5p | DNAJB2 | 0.4 | 0.2546 | 0.24 | 0.33213 | mirMAP | -0.16 | 0.00288 | NA | |
51 | hsa-miR-125b-5p | DNAJC5 | 0.4 | 0.2546 | 0.07 | 0.78359 | mirMAP | -0.2 | 9.0E-5 | NA | |
52 | hsa-miR-125b-5p | DNAL4 | 0.4 | 0.2546 | 0.24 | 0.30448 | miRNATAP | -0.14 | 0.00451 | NA | |
53 | hsa-miR-125b-5p | DNLZ | 0.4 | 0.2546 | -0.12 | 0.75549 | mirMAP | -0.26 | 0.00107 | NA | |
54 | hsa-miR-125b-5p | DPH2 | 0.4 | 0.2546 | 0.16 | 0.4742 | MirTarget | -0.12 | 0.01514 | NA | |
55 | hsa-miR-125b-5p | DTNB | 0.4 | 0.2546 | -0.02 | 0.95393 | MirTarget | -0.21 | 0.01298 | NA | |
56 | hsa-miR-125b-5p | DUS1L | 0.4 | 0.2546 | 0.11 | 0.70994 | MirTarget | -0.45 | 0 | NA | |
57 | hsa-miR-125b-5p | EIF4EBP1 | 0.4 | 0.2546 | 0.24 | 0.58363 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.43 | 0 | 17891175; 26646586 | Using a bioinformatics approach we have identified additional potential mRNA targets of one of the miRNAs miR-125b that are upregulated in prostate cancer and confirmed increased expression of one of these targets EIF4EBP1 in prostate cancer tissues;Increased expression of miR-125a and miR-125b inhibited invasion and migration of SKOV3 and OVCAR-429 ovarian cancer cells and was associated with a decrease in EIF4EBP1 expression |
58 | hsa-miR-125b-5p | EMD | 0.4 | 0.2546 | 0.09 | 0.67542 | miRNAWalker2 validate | -0.23 | 0 | NA | |
59 | hsa-miR-125b-5p | ESRP2 | 0.4 | 0.2546 | 0.84 | 0.02604 | miRNAWalker2 validate | -0.17 | 0.0402 | NA | |
60 | hsa-miR-125b-5p | ESRRA | 0.4 | 0.2546 | 0.38 | 0.20411 | MirTarget; miRNATAP | -0.25 | 0.0001 | NA | |
61 | hsa-miR-125b-5p | EVI5L | 0.4 | 0.2546 | 0.25 | 0.37151 | mirMAP | -0.14 | 0.01452 | NA | |
62 | hsa-miR-125b-5p | EXOC7 | 0.4 | 0.2546 | -0.08 | 0.63621 | miRNAWalker2 validate | -0.12 | 0.00185 | NA | |
63 | hsa-miR-125b-5p | FAM134C | 0.4 | 0.2546 | 0.08 | 0.69902 | MirTarget | -0.23 | 0 | NA | |
64 | hsa-miR-125b-5p | FAM160B2 | 0.4 | 0.2546 | -0.31 | 0.22517 | mirMAP | -0.19 | 0.00031 | NA | |
65 | hsa-miR-125b-5p | FAM174B | 0.4 | 0.2546 | 1.01 | 0.02976 | miRNATAP | -0.27 | 0.00574 | NA | |
66 | hsa-miR-125b-5p | FBXL19 | 0.4 | 0.2546 | 0.12 | 0.70344 | miRNATAP | -0.13 | 0.046 | NA | |
67 | hsa-miR-125b-5p | FBXW4 | 0.4 | 0.2546 | 0.12 | 0.63331 | MirTarget; miRNATAP | -0.18 | 0.00079 | NA | |
68 | hsa-miR-125b-5p | FCHSD1 | 0.4 | 0.2546 | -0.45 | 0.11755 | mirMAP; miRNATAP | -0.13 | 0.03992 | NA | |
69 | hsa-miR-125b-5p | FKBP2 | 0.4 | 0.2546 | 0.69 | 0.06474 | miRNATAP | -0.37 | 0 | NA | |
70 | hsa-miR-125b-5p | FRAT2 | 0.4 | 0.2546 | -0.12 | 0.73257 | miRNAWalker2 validate; miRNATAP | -0.21 | 0.00512 | NA | |
71 | hsa-miR-125b-5p | FZR1 | 0.4 | 0.2546 | 0.13 | 0.57179 | mirMAP | -0.18 | 0.00033 | NA | |
72 | hsa-miR-125b-5p | GGA1 | 0.4 | 0.2546 | -0.35 | 0.11869 | mirMAP | -0.19 | 5.0E-5 | NA | |
73 | hsa-miR-125b-5p | GLYCTK | 0.4 | 0.2546 | -0.08 | 0.86822 | MirTarget | -0.22 | 0.02352 | NA | |
74 | hsa-miR-125b-5p | GMPPB | 0.4 | 0.2546 | 0.2 | 0.34146 | mirMAP | -0.16 | 0.00019 | NA | |
75 | hsa-miR-125b-5p | GNB1L | 0.4 | 0.2546 | -0.03 | 0.94425 | mirMAP | -0.3 | 0.00106 | NA | |
76 | hsa-miR-125b-5p | GRINA | 0.4 | 0.2546 | -0.25 | 0.28766 | miRNAWalker2 validate | -0.15 | 0.00247 | NA | |
77 | hsa-miR-125b-5p | GRSF1 | 0.4 | 0.2546 | 0.37 | 0.06369 | MirTarget; miRNATAP | -0.19 | 1.0E-5 | NA | |
78 | hsa-miR-125b-5p | HAPLN1 | 0.4 | 0.2546 | 2.65 | 0.01928 | MirTarget; miRNATAP | -0.73 | 0.00259 | NA | |
79 | hsa-miR-125b-5p | HDGF | 0.4 | 0.2546 | 0.57 | 0.04237 | miRNAWalker2 validate | -0.13 | 0.0339 | NA | |
80 | hsa-miR-125b-5p | HMGA1 | 0.4 | 0.2546 | 1.07 | 0.06615 | miRNAWalker2 validate; miRTarBase | -0.32 | 0.01171 | NA | |
81 | hsa-miR-125b-5p | HMGB3 | 0.4 | 0.2546 | 0.33 | 0.36296 | miRNATAP | -0.3 | 8.0E-5 | NA | |
82 | hsa-miR-125b-5p | HSPA1B | 0.4 | 0.2546 | 1.32 | 0.02667 | miRNAWalker2 validate | -0.35 | 0.00585 | NA | |
83 | hsa-miR-125b-5p | HSPBP1 | 0.4 | 0.2546 | 0.46 | 0.19342 | miRNAWalker2 validate | -0.43 | 0 | NA | |
84 | hsa-miR-125b-5p | HSPD1 | 0.4 | 0.2546 | 0.7 | 0.01734 | miRNAWalker2 validate | -0.19 | 0.00233 | NA | |
85 | hsa-miR-125b-5p | IER3IP1 | 0.4 | 0.2546 | 0.22 | 0.36666 | MirTarget | -0.12 | 0.02371 | NA | |
86 | hsa-miR-125b-5p | ILVBL | 0.4 | 0.2546 | 0.45 | 0.11016 | miRNAWalker2 validate | -0.28 | 0 | NA | |
87 | hsa-miR-125b-5p | ITPK1 | 0.4 | 0.2546 | 0.18 | 0.47798 | mirMAP | -0.12 | 0.02932 | NA | |
88 | hsa-miR-125b-5p | JUP | 0.4 | 0.2546 | 0.75 | 0.09945 | miRNATAP | -0.21 | 0.03383 | NA | |
89 | hsa-miR-125b-5p | KDM4B | 0.4 | 0.2546 | -0.41 | 0.10162 | mirMAP | -0.24 | 0 | NA | |
90 | hsa-miR-125b-5p | KHSRP | 0.4 | 0.2546 | -0.04 | 0.82083 | miRNAWalker2 validate | -0.13 | 8.0E-5 | NA | |
91 | hsa-miR-125b-5p | KIF24 | 0.4 | 0.2546 | 0.56 | 0.1505 | miRNAWalker2 validate | -0.23 | 0.00583 | NA | |
92 | hsa-miR-125b-5p | KLC2 | 0.4 | 0.2546 | 0.33 | 0.21057 | MirTarget; miRNATAP | -0.13 | 0.0183 | 25668010 | This study is to identify the function of KLC2 and its interaction with miR-125b in NSCLC; The direct interaction between KLC2 and miR-125b was confirmed by a luciferase reporter assay and a transient co-transfection assay as well as an analysis of eight matched clinical samples; MiR-125b inhibited KLC2 3'-untranslated region luciferase activity and protein expression and inversely correlated with KLC2 expression in clinical samples |
93 | hsa-miR-125b-5p | KLF16 | 0.4 | 0.2546 | 0.45 | 0.17715 | mirMAP; miRNATAP | -0.22 | 0.00218 | NA | |
94 | hsa-miR-125b-5p | LBX2 | 0.4 | 0.2546 | 0.28 | 0.66312 | miRNAWalker2 validate | -0.31 | 0.02769 | NA | |
95 | hsa-miR-125b-5p | LMNB2 | 0.4 | 0.2546 | 0.41 | 0.13181 | mirMAP | -0.2 | 0.00048 | NA | |
96 | hsa-miR-125b-5p | LPIN3 | 0.4 | 0.2546 | 0.75 | 0.05455 | MirTarget | -0.23 | 0.00505 | NA | |
97 | hsa-miR-125b-5p | LRPAP1 | 0.4 | 0.2546 | 0.19 | 0.50518 | mirMAP | -0.24 | 9.0E-5 | NA | |
98 | hsa-miR-125b-5p | LRRC14 | 0.4 | 0.2546 | 0.1 | 0.69444 | mirMAP | -0.28 | 0 | NA | |
99 | hsa-miR-125b-5p | LSM14B | 0.4 | 0.2546 | 0.2 | 0.31201 | miRNAWalker2 validate | -0.15 | 0.00023 | NA | |
100 | hsa-miR-125b-5p | LYPLA2 | 0.4 | 0.2546 | 0.06 | 0.82818 | miRNAWalker2 validate; mirMAP; miRNATAP | -0.21 | 0.00035 | NA | |
101 | hsa-miR-125b-5p | MAP2K7 | 0.4 | 0.2546 | -0.07 | 0.76128 | miRNATAP | -0.2 | 3.0E-5 | 27226726 | miR 125b inhibited epithelial mesenchymal transition of triple negative breast cancer by targeting MAP2K7; Upregulation of MAP2K7 in miR-125b-overexpressing Hs578T cells partly rescued the migration and invasion suppression of miR-125b; Furthermore MAP2K7 was overexpressed in TNBC samples compared with normal tissues and negatively correlated with miR-125b expression; In light of these findings miR-125b emerged as a tumor suppressor in TNBC by targeting MAP2K7 to inhibit EMT |
102 | hsa-miR-125b-5p | MAP3K10 | 0.4 | 0.2546 | -0.02 | 0.96185 | MirTarget; miRNATAP | -0.2 | 0.00475 | NA | |
103 | hsa-miR-125b-5p | MAP3K11 | 0.4 | 0.2546 | 0.07 | 0.78544 | miRNATAP | -0.19 | 0.00047 | 24635082 | Expression of the miRNA miR-125b and serine/threonine kinase mixed lineage kinase MLK3 was assessed in primary malignant melanoma tissues and several melanoma cell lines by quantitative reverse transcription PCR; The effect of MLK3 and miR-125b on cell proliferation was evaluated by MTS assay and cell invasion was evaluated by Transwell invasion assays; Targeting of MLK3 by miR-125b was evaluated using luciferase reporter assay and western blotting; Using bioinformatics we identified MLK3 as one potential target of miR-125b; miRNA transfection and luciferase assay confirmed that MLK3 was regulated by miR-125b at both the transcriptional and translational levels; MLK3 is a direct target of miR-125b |
104 | hsa-miR-125b-5p | MED15 | 0.4 | 0.2546 | -0.09 | 0.73343 | miRNATAP | -0.12 | 0.03057 | NA | |
105 | hsa-miR-125b-5p | MED22 | 0.4 | 0.2546 | -0.22 | 0.24916 | mirMAP | -0.14 | 0.00041 | NA | |
106 | hsa-miR-125b-5p | METRN | 0.4 | 0.2546 | 0.26 | 0.71297 | mirMAP | -0.61 | 6.0E-5 | NA | |
107 | hsa-miR-125b-5p | MICAL3 | 0.4 | 0.2546 | -0.78 | 0.00521 | mirMAP | -0.12 | 0.04992 | NA | |
108 | hsa-miR-125b-5p | MKNK2 | 0.4 | 0.2546 | 0.13 | 0.63494 | miRNAWalker2 validate; MirTarget | -0.2 | 0.00049 | NA | |
109 | hsa-miR-125b-5p | MLEC | 0.4 | 0.2546 | 0.23 | 0.3659 | mirMAP | -0.12 | 0.02195 | NA | |
110 | hsa-miR-125b-5p | MLF2 | 0.4 | 0.2546 | 0.18 | 0.48575 | miRNATAP | -0.3 | 0 | NA | |
111 | hsa-miR-125b-5p | MMAB | 0.4 | 0.2546 | 0.22 | 0.49087 | miRNAWalker2 validate | -0.32 | 0 | NA | |
112 | hsa-miR-125b-5p | MOGS | 0.4 | 0.2546 | 0.19 | 0.33749 | mirMAP | -0.28 | 0 | NA | |
113 | hsa-miR-125b-5p | MRTO4 | 0.4 | 0.2546 | 0.17 | 0.44284 | miRNAWalker2 validate | -0.16 | 0.00069 | NA | |
114 | hsa-miR-125b-5p | MTMR4 | 0.4 | 0.2546 | -0.38 | 0.11171 | miRNAWalker2 validate | -0.1 | 0.04294 | NA | |
115 | hsa-miR-125b-5p | MTSS1L | 0.4 | 0.2546 | -0.08 | 0.81529 | MirTarget; mirMAP | -0.17 | 0.01909 | NA | |
116 | hsa-miR-125b-5p | MYO19 | 0.4 | 0.2546 | 0.45 | 0.10934 | miRNAWalker2 validate | -0.27 | 0 | NA | |
117 | hsa-miR-125b-5p | NACC1 | 0.4 | 0.2546 | 0.19 | 0.37573 | mirMAP | -0.17 | 0.00017 | NA | |
118 | hsa-miR-125b-5p | NCLN | 0.4 | 0.2546 | 0.21 | 0.50113 | mirMAP | -0.38 | 0 | NA | |
119 | hsa-miR-125b-5p | NCOR2 | 0.4 | 0.2546 | 0.06 | 0.82568 | MirTarget; miRNATAP | -0.12 | 0.03342 | NA | |
120 | hsa-miR-125b-5p | NDOR1 | 0.4 | 0.2546 | 0.09 | 0.7985 | miRNAWalker2 validate | -0.35 | 0 | NA | |
121 | hsa-miR-125b-5p | NDUFA2 | 0.4 | 0.2546 | 0.21 | 0.41146 | MirTarget | -0.27 | 0 | NA | |
122 | hsa-miR-125b-5p | NECAB3 | 0.4 | 0.2546 | 0.55 | 0.14976 | miRNATAP | -0.43 | 0 | NA | |
123 | hsa-miR-125b-5p | NEU1 | 0.4 | 0.2546 | -0.06 | 0.84112 | miRNATAP | -0.21 | 0.00154 | 25184537; 27220320 | Thus far two of these target genes BBC3 and NEU1 that are tumor suppressor genes but not yet studied in PDAC appear to be functional targets of miR-125b since knockdown of miR125b caused their up regulation;STARD13 and NEU1 were identified as direct target genes of miR-125b by luciferase assays and they were involved in the cell migration and invasion regulated by miR-125b in gastric cancer |
124 | hsa-miR-125b-5p | NME2 | 0.4 | 0.2546 | 0.4 | 0.22385 | miRNAWalker2 validate | -0.22 | 0.00147 | NA | |
125 | hsa-miR-125b-5p | NSUN2 | 0.4 | 0.2546 | 0.23 | 0.22827 | miRNAWalker2 validate | -0.19 | 0 | NA | |
126 | hsa-miR-125b-5p | PACS2 | 0.4 | 0.2546 | -0.2 | 0.37407 | mirMAP | -0.14 | 0.00233 | NA | |
127 | hsa-miR-125b-5p | PAN2 | 0.4 | 0.2546 | -0.33 | 0.28947 | MirTarget; miRNATAP | -0.15 | 0.02681 | NA | |
128 | hsa-miR-125b-5p | PCTP | 0.4 | 0.2546 | 0.2 | 0.43846 | MirTarget; miRNATAP | -0.15 | 0.00584 | NA | |
129 | hsa-miR-125b-5p | PDDC1 | 0.4 | 0.2546 | 0.12 | 0.65355 | mirMAP | -0.17 | 0.00284 | NA | |
130 | hsa-miR-125b-5p | PDIA3 | 0.4 | 0.2546 | 0.55 | 0.01531 | MirTarget | -0.15 | 0.00207 | NA | |
131 | hsa-miR-125b-5p | PDZD11 | 0.4 | 0.2546 | 0.42 | 0.04359 | miRNAWalker2 validate | -0.17 | 0.00014 | NA | |
132 | hsa-miR-125b-5p | PFDN6 | 0.4 | 0.2546 | 0.38 | 0.16972 | mirMAP | -0.27 | 0 | NA | |
133 | hsa-miR-125b-5p | PIGZ | 0.4 | 0.2546 | 0.29 | 0.43554 | mirMAP | -0.21 | 0.00798 | NA | |
134 | hsa-miR-125b-5p | PLAGL2 | 0.4 | 0.2546 | -0.01 | 0.97433 | mirMAP; miRNATAP | -0.1 | 0.04158 | NA | |
135 | hsa-miR-125b-5p | PMM2 | 0.4 | 0.2546 | 0.58 | 0.02319 | MirTarget | -0.24 | 1.0E-5 | NA | |
136 | hsa-miR-125b-5p | PPIF | 0.4 | 0.2546 | 0.04 | 0.90608 | MirTarget | -0.29 | 2.0E-5 | NA | |
137 | hsa-miR-125b-5p | PPP1CA | 0.4 | 0.2546 | 0.06 | 0.78484 | miRTarBase | -0.2 | 7.0E-5 | 25240408 | MiR 125b promotes cell migration and invasion by targeting PPP1CA Rb signal pathways in gastric cancer resulting in a poor prognosis; MiR-125b was upregulated in gastric cancer tissues and cell lines and significantly promoted cellular proliferation migration and invasion by downregulating the expression of PPP1CA and upregulating Rb phosphorylation; MiR-125b functions as an oncogene by targeting downregulated PPP1CA and upregulated Rb phosphorylation in gastric cancer |
138 | hsa-miR-125b-5p | PRDX2 | 0.4 | 0.2546 | 0.35 | 0.25619 | miRNAWalker2 validate | -0.25 | 8.0E-5 | 22213330 | Treatment with 5-Aza but not with TSA reduced the expression of miR-125b in the 125OH2D3-responsive and -resistant melanoma cell lines and in the NHM |
139 | hsa-miR-125b-5p | PSAT1 | 0.4 | 0.2546 | 0.16 | 0.83048 | miRNAWalker2 validate | -0.48 | 0.00225 | NA | |
140 | hsa-miR-125b-5p | PSMB1 | 0.4 | 0.2546 | 0.04 | 0.84214 | miRNAWalker2 validate | -0.14 | 0.0017 | NA | |
141 | hsa-miR-125b-5p | PSMG3 | 0.4 | 0.2546 | 0.5 | 0.15363 | MirTarget | -0.45 | 0 | NA | |
142 | hsa-miR-125b-5p | PTOV1 | 0.4 | 0.2546 | 0.25 | 0.44824 | miRNAWalker2 validate | -0.36 | 0 | NA | |
143 | hsa-miR-125b-5p | PXMP4 | 0.4 | 0.2546 | 0.35 | 0.12613 | MirTarget | -0.18 | 0.00019 | NA | |
144 | hsa-miR-125b-5p | PYCRL | 0.4 | 0.2546 | 0.66 | 0.05406 | mirMAP | -0.44 | 0 | NA | |
145 | hsa-miR-125b-5p | QSOX2 | 0.4 | 0.2546 | -0.02 | 0.94598 | miRNAWalker2 validate; miRNATAP | -0.14 | 0.02304 | NA | |
146 | hsa-miR-125b-5p | RAB3D | 0.4 | 0.2546 | 0.8 | 0.03026 | MirTarget; miRNATAP | -0.29 | 0.00023 | NA | |
147 | hsa-miR-125b-5p | RBM38 | 0.4 | 0.2546 | -0.51 | 0.27773 | miRNATAP | -0.27 | 0.00798 | NA | |
148 | hsa-miR-125b-5p | RFC5 | 0.4 | 0.2546 | 0.13 | 0.54799 | MirTarget | -0.17 | 0.00024 | NA | |
149 | hsa-miR-125b-5p | RFT1 | 0.4 | 0.2546 | 0.07 | 0.69071 | mirMAP | -0.16 | 3.0E-5 | NA | |
150 | hsa-miR-125b-5p | RFXANK | 0.4 | 0.2546 | -0 | 0.99034 | MirTarget | -0.32 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | PROTEIN FOLDING | 14 | 224 | 1.993e-07 | 0.0009272 |
2 | MITOCHONDRIAL TRANSPORT | 12 | 177 | 6.376e-07 | 0.001483 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | ORGANELLE INNER MEMBRANE | 21 | 525 | 3.807e-07 | 0.0002224 |
2 | MITOCHONDRION | 40 | 1633 | 1.27e-06 | 0.0003707 |
3 | ENVELOPE | 29 | 1090 | 9.668e-06 | 0.001412 |
4 | MITOCHONDRIAL ENVELOPE | 22 | 691 | 8.387e-06 | 0.001412 |
5 | MITOCHONDRIAL MEMBRANE PART | 10 | 173 | 2.256e-05 | 0.002196 |
6 | MITOCHONDRIAL PART | 26 | 953 | 1.894e-05 | 0.002196 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Apoptosis_hsa04210 | 5 | 138 | 0.01837 | 0.9162 | |
2 | Apoptosis_multiple_species_hsa04215 | 2 | 33 | 0.05088 | 0.9162 | |
3 | ErbB_signaling_pathway_hsa04012 | 3 | 85 | 0.06734 | 0.9162 | |
4 | HIF_1_signaling_pathway_hsa04066 | 3 | 100 | 0.09812 | 0.9162 | |
5 | Cellular_senescence_hsa04218 | 4 | 160 | 0.1005 | 0.9162 | |
6 | cGMP_PKG_signaling_pathway_hsa04022 | 4 | 163 | 0.1057 | 0.9162 | |
7 | AMPK_signaling_pathway_hsa04152 | 3 | 121 | 0.1487 | 0.9659 | |
8 | Lysosome_hsa04142 | 3 | 123 | 0.1539 | 0.9659 | |
9 | Autophagy_animal_hsa04140 | 3 | 128 | 0.1672 | 0.9659 | |
10 | MAPK_signaling_pathway_hsa04010 | 5 | 295 | 0.2257 | 1 | |
11 | mTOR_signaling_pathway_hsa04150 | 3 | 151 | 0.2317 | 1 | |
12 | Phosphatidylinositol_signaling_system_hsa04070 | 2 | 99 | 0.2972 | 1 | |
13 | TNF_signaling_pathway_hsa04668 | 2 | 108 | 0.3336 | 1 | |
14 | Wnt_signaling_pathway_hsa04310 | 2 | 146 | 0.4788 | 1 | |
15 | Endocytosis_hsa04144 | 3 | 244 | 0.5044 | 1 | |
16 | Hippo_signaling_pathway_hsa04390 | 2 | 154 | 0.5069 | 1 | |
17 | Necroptosis_hsa04217 | 2 | 164 | 0.5406 | 1 | |
18 | Tight_junction_hsa04530 | 2 | 170 | 0.5601 | 1 | |
19 | Calcium_signaling_pathway_hsa04020 | 2 | 182 | 0.5973 | 1 | |
20 | cAMP_signaling_pathway_hsa04024 | 2 | 198 | 0.6431 | 1 | |
21 | Focal_adhesion_hsa04510 | 2 | 199 | 0.6458 | 1 | |
22 | PI3K_Akt_signaling_pathway_hsa04151 | 3 | 352 | 0.7467 | 1 |